Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Lux

Showing results (81-90 of 233) with videos related to

Pageof 24
Sort By:
Breast Cancer Research and Treatment|October 13, 2006
The impact of breast cancer awareness and socioeconomic status on willingness to receive breast cancer prevention drugsPeter A Fasching, Gunter von Minckwitz, Thorsten Fischer, et al.
Geburtshilfe Und Frauenheilkunde|December 8, 2015
Health Services Research and Health Economy - Quality Care Training in Gynaecology, with Focus On Gynaecological OncologyM P Lux, P A Fasching, C R Loehberg, et al.
Journal of Cancer Research and Clinical Oncology|April 5, 2008
Polymorphisms in the novel serotonin receptor subunit gene HTR3C show different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapyP A Fasching, B Kollmannsberger, P L Strissel, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 29, 2011
The GISS trial: a phase II prevention trial of screening plus goserelin, ibandronate, versus screening alone in premenopausal women at increased risk of breast cancerGunter von Minckwitz, Sibylle Loibl, Christian Jackisch, et al.
Breast Cancer Research and Treatment|March 15, 2019
Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positive early breast cancerPeter A Fasching, Paul Gass, Lothar Häberle, et al.
Breast (Edinburgh, Scotland)|April 4, 2009
Ki-67 as a prognostic molecular marker in routine clinical use in breast cancer patientsFolkward G Wiesner, Achim Magener, Peter A Fasching, et al.
Breast (Edinburgh, Scotland)|February 26, 2023
Imaging of lumpectomy surface with large field-of-view confocal laser scanning microscopy 'Histolog® scanner' for breast margin assessment in comparison with conventional specimen radiographyRiku Togawa, Johanna Hederer, Moira Ragazzi, et al.
Archives of Gynecology and Obstetrics|September 8, 2012
Prognostic molecular markers and neoadjuvant therapy response in anthracycline-treated breast cancer patientsDavid L Wachter, Peter A Fasching, Lothar Haeberle, et al.
Anticancer Research|February 11, 2014
Health utilities in gynecological oncology and mastology in GermanyThomas Hildebrandt, Falk C Thiel, Peter A Fasching, et al.
Journal of Cancer Research and Clinical Oncology|January 6, 2020
Long-term outcome of patients with intermediate- and high-risk endometrial cancer after pelvic and paraaortic lymph node dissection: a comparison of laparoscopic vs. open procedureThomas Papathemelis, Helen Oppermann, Stella Grafl, et al.
Pageof 24

Showing results (81-90 of 233) with videos related to

Sort By:
Pageof 24
Breast Cancer Research and Treatment|October 13, 2006
The impact of breast cancer awareness and socioeconomic status on willingness to receive breast cancer prevention drugsPeter A Fasching, Gunter von Minckwitz, Thorsten Fischer, et al.
Geburtshilfe Und Frauenheilkunde|December 8, 2015
Health Services Research and Health Economy - Quality Care Training in Gynaecology, with Focus On Gynaecological OncologyM P Lux, P A Fasching, C R Loehberg, et al.
Journal of Cancer Research and Clinical Oncology|April 5, 2008
Polymorphisms in the novel serotonin receptor subunit gene HTR3C show different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapyP A Fasching, B Kollmannsberger, P L Strissel, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 29, 2011
The GISS trial: a phase II prevention trial of screening plus goserelin, ibandronate, versus screening alone in premenopausal women at increased risk of breast cancerGunter von Minckwitz, Sibylle Loibl, Christian Jackisch, et al.
Breast Cancer Research and Treatment|March 15, 2019
Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positive early breast cancerPeter A Fasching, Paul Gass, Lothar Häberle, et al.
Breast (Edinburgh, Scotland)|April 4, 2009
Ki-67 as a prognostic molecular marker in routine clinical use in breast cancer patientsFolkward G Wiesner, Achim Magener, Peter A Fasching, et al.
Breast (Edinburgh, Scotland)|February 26, 2023
Imaging of lumpectomy surface with large field-of-view confocal laser scanning microscopy 'Histolog® scanner' for breast margin assessment in comparison with conventional specimen radiographyRiku Togawa, Johanna Hederer, Moira Ragazzi, et al.
Archives of Gynecology and Obstetrics|September 8, 2012
Prognostic molecular markers and neoadjuvant therapy response in anthracycline-treated breast cancer patientsDavid L Wachter, Peter A Fasching, Lothar Haeberle, et al.
Anticancer Research|February 11, 2014
Health utilities in gynecological oncology and mastology in GermanyThomas Hildebrandt, Falk C Thiel, Peter A Fasching, et al.
Journal of Cancer Research and Clinical Oncology|January 6, 2020
Long-term outcome of patients with intermediate- and high-risk endometrial cancer after pelvic and paraaortic lymph node dissection: a comparison of laparoscopic vs. open procedureThomas Papathemelis, Helen Oppermann, Stella Grafl, et al.
Pageof 24